And to ask what other prescribed medication awards GPs with financial incentives?
Beginning in April 2026, GPs in England will receive financial incentives, averaging £3,000 a year, to increase the prescription of weight-loss drugs, specifically Mounjaro (tirzepatide), to eligible patients. This move is part of a government initiative to accelerate the NHS rollout of these treatments to manage obesity, with up to £25 million in ring-fenced funding.
BBC +2
Key Aspects of the New Initiative:
-
Targeted Incentives: The bonus is intended to encourage GP practices to prescribe Mounjaro to those with the greatest clinical need, rather than just those who can afford private prescriptions.
-
Eligibility Restrictions: Despite the push, access remains restricted to specific groups. Initially, this includes patients with a BMI of 40 or higher (or 37.5 for certain ethnic groups) who also have at least four weight-related conditions. The eligibility threshold is expected to drop in 2026/27.
-
Concerns over Implementation: While aimed at improving access, some GP leaders and experts have voiced concerns that the incentives may not overcome the "stark divide" in access and could strain GP workloads.
-
Alternative Care Models: Amidst the focus on medication, some GPs are also expanding "social prescribing" to improve mental and physical health through non-clinical activities like community projects, which can in some cases reduce the need for medication.
- BBC +5
The move follows a broader push to make weight-loss treatments "to the many, not the few," aiming to reduce the long-term health burdens on the NHS.